Cargando…

Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial Stiffness

INTRODUCTION: The presence of cardiovascular (CV) risk factors and CV disease in patients with chronic obstructive pulmonary disease (COPD) leads to worse outcomes. A number of tools are currently available to stratify the risk of adverse outcomes in these patients with COPD. This post hoc analysis...

Descripción completa

Detalles Bibliográficos
Autores principales: Horne, Benjamin D, Ali, Rehan, Midwinter, Dawn, Scott-Wilson, Catherine, Crim, Courtney, Miller, Bruce E, Rubin, David B
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802087/
https://www.ncbi.nlm.nih.gov/pubmed/33447025
http://dx.doi.org/10.2147/COPD.S279645
_version_ 1783635699716587520
author Horne, Benjamin D
Ali, Rehan
Midwinter, Dawn
Scott-Wilson, Catherine
Crim, Courtney
Miller, Bruce E
Rubin, David B
author_facet Horne, Benjamin D
Ali, Rehan
Midwinter, Dawn
Scott-Wilson, Catherine
Crim, Courtney
Miller, Bruce E
Rubin, David B
author_sort Horne, Benjamin D
collection PubMed
description INTRODUCTION: The presence of cardiovascular (CV) risk factors and CV disease in patients with chronic obstructive pulmonary disease (COPD) leads to worse outcomes. A number of tools are currently available to stratify the risk of adverse outcomes in these patients with COPD. This post hoc analysis evaluated the Summit Lab Score for validation as a predictor of the first episode of moderate-to-severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and other outcomes, in patients with COPD and high arterial pulse wave velocity (aPWV). METHODS: Data from a multicenter, randomized, placebo-controlled, double-blind study were retrospectively analyzed to evaluate treatment effects of once-daily fluticasone furoate/vilanterol 100/25 μg in patients with COPD and an elevated CV risk (aPWV≥11m/s) over 24 weeks. The previously derived Summit Lab Score and, secondarily, the Intermountain Risk Score (IMRS) were computed for each patient, with patients then stratified into tertiles for each score. Risk of moderate-to-severe AECOPD was analyzed across tertiles using Kaplan–Meier survival curve and Cox regression analyses. RESULTS: In 430 patients with COPD, Kaplan–Meier probabilities of no moderate-to-severe AECOPD for Summit Lab Score tertiles 1, 2, and 3 were 92.3%, 95.5%, and 85.1%, respectively (P trend = 0.015), over 24 weeks. Grouped by IMRS tertiles, the respective probabilities were 92.9%, 91.2%, and 88.3%, respectively (P trend = 0.141). Length of stay in the hospital (P = 0.034) and the hospital ward (P = 0.042) were also significantly different between Summit Lab Score tertiles but not for intensive care (P = 0.191). CONCLUSION: The Summit Lab Score was associated with the 24-week risk of moderate-to-severe AECOPD in COPD patients with elevated CV risk. Secondarily, IMRS showed a trend towards differences in the risk of AECOPD, which was not statistically significant.
format Online
Article
Text
id pubmed-7802087
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-78020872021-01-13 Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial Stiffness Horne, Benjamin D Ali, Rehan Midwinter, Dawn Scott-Wilson, Catherine Crim, Courtney Miller, Bruce E Rubin, David B Int J Chron Obstruct Pulmon Dis Original Research INTRODUCTION: The presence of cardiovascular (CV) risk factors and CV disease in patients with chronic obstructive pulmonary disease (COPD) leads to worse outcomes. A number of tools are currently available to stratify the risk of adverse outcomes in these patients with COPD. This post hoc analysis evaluated the Summit Lab Score for validation as a predictor of the first episode of moderate-to-severe acute exacerbation of chronic obstructive pulmonary disease (AECOPD) and other outcomes, in patients with COPD and high arterial pulse wave velocity (aPWV). METHODS: Data from a multicenter, randomized, placebo-controlled, double-blind study were retrospectively analyzed to evaluate treatment effects of once-daily fluticasone furoate/vilanterol 100/25 μg in patients with COPD and an elevated CV risk (aPWV≥11m/s) over 24 weeks. The previously derived Summit Lab Score and, secondarily, the Intermountain Risk Score (IMRS) were computed for each patient, with patients then stratified into tertiles for each score. Risk of moderate-to-severe AECOPD was analyzed across tertiles using Kaplan–Meier survival curve and Cox regression analyses. RESULTS: In 430 patients with COPD, Kaplan–Meier probabilities of no moderate-to-severe AECOPD for Summit Lab Score tertiles 1, 2, and 3 were 92.3%, 95.5%, and 85.1%, respectively (P trend = 0.015), over 24 weeks. Grouped by IMRS tertiles, the respective probabilities were 92.9%, 91.2%, and 88.3%, respectively (P trend = 0.141). Length of stay in the hospital (P = 0.034) and the hospital ward (P = 0.042) were also significantly different between Summit Lab Score tertiles but not for intensive care (P = 0.191). CONCLUSION: The Summit Lab Score was associated with the 24-week risk of moderate-to-severe AECOPD in COPD patients with elevated CV risk. Secondarily, IMRS showed a trend towards differences in the risk of AECOPD, which was not statistically significant. Dove 2021-01-07 /pmc/articles/PMC7802087/ /pubmed/33447025 http://dx.doi.org/10.2147/COPD.S279645 Text en © 2021 Horne et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Horne, Benjamin D
Ali, Rehan
Midwinter, Dawn
Scott-Wilson, Catherine
Crim, Courtney
Miller, Bruce E
Rubin, David B
Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial Stiffness
title Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial Stiffness
title_full Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial Stiffness
title_fullStr Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial Stiffness
title_full_unstemmed Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial Stiffness
title_short Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial Stiffness
title_sort validation of the summit lab score in predicting exacerbations of chronic obstructive pulmonary disease among individuals with high arterial stiffness
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7802087/
https://www.ncbi.nlm.nih.gov/pubmed/33447025
http://dx.doi.org/10.2147/COPD.S279645
work_keys_str_mv AT hornebenjamind validationofthesummitlabscoreinpredictingexacerbationsofchronicobstructivepulmonarydiseaseamongindividualswithhigharterialstiffness
AT alirehan validationofthesummitlabscoreinpredictingexacerbationsofchronicobstructivepulmonarydiseaseamongindividualswithhigharterialstiffness
AT midwinterdawn validationofthesummitlabscoreinpredictingexacerbationsofchronicobstructivepulmonarydiseaseamongindividualswithhigharterialstiffness
AT scottwilsoncatherine validationofthesummitlabscoreinpredictingexacerbationsofchronicobstructivepulmonarydiseaseamongindividualswithhigharterialstiffness
AT crimcourtney validationofthesummitlabscoreinpredictingexacerbationsofchronicobstructivepulmonarydiseaseamongindividualswithhigharterialstiffness
AT millerbrucee validationofthesummitlabscoreinpredictingexacerbationsofchronicobstructivepulmonarydiseaseamongindividualswithhigharterialstiffness
AT rubindavidb validationofthesummitlabscoreinpredictingexacerbationsofchronicobstructivepulmonarydiseaseamongindividualswithhigharterialstiffness